{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Dose limiting toxicities (DLT) will be monitored for Phase 1 patients for the first 21 days of Induction (the DLT monitoring period) to evaluate safety. In general, a non-hematologic DLT is defined as any Grade ≥ 3 toxicity, and a hematologic DLT is defined as any Grade ≥ 4 toxicity, both by CTCAE v4.03 criteria.","groups":[{"description":"Induction:\n\n* Brentuximab vedotin 1.2 mg/kg IV infusion over 30 minutes, weekly x 3 (1 cycle = 4 weeks\n* Rituximab 375 mg/m2 IV infusion per standard protocol, once weekly for 4 weeks (1 cycle = 4 weeks)\n\nConsolidation (optional): Identical to Induction.\n\nMaintenance:\n\n* Brentuximab vedotin 1.8 mg/kg IV infusion over 30 minutes once every 3 weeks (1 cycle = 3 weeks), for a total of one year from the first induction dose or until progression of disease.\n* Rituximab 375 mg/m2 IV infusion per standard protocol, once every 6 weeks for a total of one year from the first induction dose or until progression of disease.","id":"OG000","title":"Brentuximb Vedotin Dose Level 1 (1.2 mg/kg)"}],"paramType":"NUMBER","populationDescription":"Six patients in Phase 1 received dose level 1 of brentuximab vedotin (1.2 mg/kg IV).","reportingStatus":"POSTED","timeFrame":"The first 21 days of induction","title":"Phase 1: Number of Dose Limiting Toxicities of Brentuximab Vedotin and Rituximab in Patients With Immunosuppressed Lymphoid Malignancies.","type":"PRIMARY","unitOfMeasure":"Grade 3 hyponatremia"}